Navigation Links
Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
Date:3/21/2013

eries is very exciting and gratifying milestone for us."

Concurrent with FREEDOM-1, Intarcia will also be conducting an open-label study, called FREEDOM-1 HBL (high baseline), in patients who meet all eligibility criteria for FREEDOM-1, but whose baseline HbA1c is greater than 10%. All patients in this study will be treated with ITCA 650 20 mcg/d for the first 3 months and with ITCA 650 60 mcg/d for the next 6 months.

About the FREEDOM Program

The FREEDOM program is designed to evaluate the safety and efficacy of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes. Intarcia expects to enroll greater than 4,000 patients at more than 500 clinical trial sites in more than 30 countries. The clinical studies will cover a broad range of patients whose diabetes is not controlled by oral anti-diabetes medications including metformin and metformin-based combinations. FREEDOM-1 is a U.S.-only, placebo-controlled, double-blind study comparing ITCA 650 doses of 40 mcg/d and 60 mcg/d to placebo; the FREEDOM-2 study will be a 500-patient, global, active-comparator controlled, double-blind, double-dummy study in patients on metformin only, comparing ITCA 650 20 mcg/d for 13 weeks plus ITCA 650 60 mcg/d for 39 weeks to patients taking sitagliptin (Januvia®, Merck); FREEDOM-CVO is a global, placebo-controlled cardiovascular outcomes study that will examine the safety of ITCA 650 at 60 mcg/d vs. placebo in approximately 3,000 patients on a variety of approved anti-diabetes therapies.

About ITCA 650

ITCA 650 (continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
3. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
4. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
5. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
6. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
7. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
8. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
9. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
10. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
11. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... DUBLIN , June 24, 2015 ... has announced the addition of the "Future ... Banking Market 2015: Supplier Shares and Country Forecasts" ... Horizons and Growth Strategies in the European Blood ... prepared in order to help current suppliers and ...
(Date:7/1/2015)... DIEGO , July 1, 2015  AVACEN, Inc. announced ... second AVACEN patent covering the medical technology platform supporting its ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... apparatus and methods patent no. 9,066,781 - Methods And Apparatus ... manufactured by AVACEN and specific methods of use, referred to ...
(Date:7/1/2015)...  Genoa has acquired West Bend Assisted Living Pharmacy ... location with a proven track record for excellent service ... and those involved in their care. Both companies have ... true value to their customers. ... pharmacy services dedicated to the behavioral health community and ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3AVACEN Medical Patent Issued 2Genoa, a QoL Healthcare Company Acquires West Bend Assisted Living Pharmacy 2
... Dec. 13, 2011 Sotera Wireless, Inc. today announced ... led by Singapore-based global fund, EDBI. The round also ... Ventures, Qualcomm Ventures, Intel Capital and West Health Investment ... commercial agreement with Cerner, a leading health care technology ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") ... advanced in-vitro diagnostic ("IVD") company, today announced that ... plan to improve its balance sheet. The plan ... existing holders of the Company,s convertible notes maturing ...
Cached Medicine Technology:Sotera Wireless Completes $12.2 Million Series D Financing, Signs Agreement with Cerner 2China Medical Technologies Intends to Implement Debt Restructuring 2
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope ... in the Twin Cities on Saturday, August 1, at Spring Lake Park High School. ... provide more than $1 million worth of goods and services including free food, health ...
(Date:7/1/2015)... ... 01, 2015 , ... RowdMap Inc. is a proud participant ... “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care Transformation Task ... http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group of private ...
(Date:7/1/2015)... OH (PRWEB) , ... July 01, 2015 , ... Franklin ... to announce Dr. Leslie King has been named Dean of the ... as Dean, Dr. King will promote and support the vision and mission of Franklin ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, the ... Customers purchasing two or more Bunion Booties directly from their website, http://www.BunionBootie.com ... temporarily corrects misaligned toes and its ultra thin properties allow for protection against ...
(Date:7/1/2015)... ... ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively to ... for Capital Health in Pennington, N.J. One of the top ... more than 1,000 healthcare executives into organizations. , Capital Health is a two-hospital ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... partly to blame for the conflict in Sudan's Darfur ... U.N. Secretary-General Ban Ki-moon said in an editorial published ... in convenient military and political shorthand - an ethnic ... Ban wrote in The Washington Post. "Look to its ...
... identified individual genes that are associated with resistance to ... that may significantly enhance the ability to predict ... treatment,using a functional genomic screen. ,Resistance to ... in patients with metastatic cancer. Dr. Julian Downward from ...
... and TV presenter Charlotte Church has been preparing her playlist of ... if reports have to be believed . ,It seems ... with beau Gavin Henson, hopes that the iTunes will help her ... insider said that the Rugby star had consulted his friends, who ...
... announced that the wrappers of the diabetes drug Avandia will ... risk of congestive heart failure . ,Some of ... FDA, feel that the delay in implementation is an example ... loser. ,GlaxoSmithKline's Avandia has been in use since ...
... cancer, has been conferred the honor of CBE in the ... Leeds in UK , was first diagnosed with breast cancer ... returned to haunt her a decade later, spreading to her ... was told six years ago. ,But undaunted she ...
... (RIA Novosti) Astronauts from the Atlantis space shuttle have ... Station (ISS), a spokesperson for the US National Aeronautics ... ,During the space walk, astronauts Patrick Forrester and Steven ... (SARJ), allowing solar arrays installed earlier to rotate towards ...
Cached Medicine News:Health News:Climatic Change Cause of Dafur Conflict-UN 2Health News:New Genetic Studies Carried Out in Cancer Therapy 2Health News:42-year-old Cancer Patient Honored by British Queen for Her Fundraising Efforts 2
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Anti Gliadin IgG Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... System - A Single Platform for ... with true load-and-go productivity and maximized ... and UF-100 for complete walkaway urinalysis. ... together deliver utmost reliability. Ease of ...
... is one of the 3 major naturally ... estrone). In terms of estrogenic activity, estriol ... Estriol is produced almost exclusively during pregnancy, ... the normal human fetus. During pregnancy, the ...
Medicine Products: